Ascendis Pharma A/S (ASND) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Ascendis Pharma A/S (ASND) trades at a price-to-earnings ratio of -54.7x, with a stock price of $233.50 and trailing twelve-month earnings per share of $-3.71.
Compared to the Healthcare sector median P/E of 23.7x, ASND trades at a 331% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, ASND trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ASND DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Commercial Rare Disease Biopharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
VRTXVertex Pharmaceuticals Incorporated | $126B | 32.4 | 3.91 | +837% |
BMRNBioMarin Pharmaceutical Inc. | $12B | 34.3 | - | +1186%Best |
PTCTPTC Therapeutics, Inc. | $5B | 8.8 | - | +264% |
CORTCorcept Therapeutics Incorporated | $4B | 43.5 | - | -33% |
CPRXCatalyst Pharmaceuticals, Inc. | $3B | 13.7 | 0.73Best | +28% |
BCRXBioCryst Pharmaceuticals, Inc. | $2B | 7.2Lowest | - | +381% |
HRMYHarmony Biosciences Holdings, Inc. | $2B | 10.5 | - | +8% |
PLXProtalix BioTherapeutics, Inc. | $218M | 78.7 | - | -63% |
SLNOSoleno Therapeutics, Inc. | $145,692 | 100.2 | - | +109% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See ASND's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ASND Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ASND vs AGIO
See how ASND stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ASND stock overvalued or undervalued?
ASND current P/E: -54.7x. 5-year average P/E: N/A. Percentile: N/A.
How does ASND's valuation compare to peers?
Ascendis Pharma A/S P/E of -54.7x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is ASND's PEG ratio?
ASND PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.